Article Information
History
- December 16, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kipper Fletez-Brant1,6,&,
- Renan Sauteraud1,
- Yanyu Liang2,^,
- Steven Micheletti2,^,
- Priyanka Nandakumar2,^,
- Aarathi Sugathan1,7,^,
- Kijoung Song3,8,
- Taylor B. Cavazos1,9,
- Amal Thomas1,10,
- Robert J. Tunney1,
- Barry Hicks2,
- Jared O’Connell2,11,
- Suyash Shringarpure2,
- Katelyn Kukar2,
- Meghan Moreno2,
- Emily DelloRusso2,
- Corinna D. Wong2,
- Aaron Petrakovitz2,12,
- Goutham Atla4,13,
- Adrian Cortes4,
- Padhraig Gormley5,
- Laurence Howe4,
- Rajashree Mishra3,
- Daniel Seaton4,
- the 23andMe Research Team&,
- Robert C. Gentleman1,14,
- Steven J. Pitts1,2 and
- Vladimir Vacic1,&
- 1Therapeutics Division, 23andMe, Inc., South San Francisco, CA, USA
- 223andMe, Inc., Sunnyvale, CA, USA
- 3Genomic Sciences, GSK, Upper Providence, PA, USA
- 4Genomic Sciences, GSK, Stevenage, UK
- 5Genomic Sciences, GSK, Cambridge, MA, USA
- 6Genentech, Inc., South San Francisco, CA, USA
- 7CSL, Melbourne, VIC, Australia
- 8Alumis, South San Francisco, CA, USA
- 9Exai Bio, Inc., Palo Alto, CA, USA
- 10Gilead Sciences, Inc., Foster City, CA, USA
- 11AstraZeneca PLC, Barcelona, Catalonia, Spain
- 12Genomenon, Inc., Ann Arbor, MI, USA
- 13Novo Nordisk Research Centre Oxford Ltd, Oxford, UK
- 14Center for Computational Biomedicine, Harvard Medical School, Boston, MA, USA
- ↵&To whom correspondence should be addressed at fletezbk{at}gene.com, research-inquiries{at}23andme.com and vvacic{at}gmail.com.
↵^ These authors contributed equally.